Keryx Biopharmaceuticals Inc. (KERX) CEO Ron Bentsur buys 5,560 Shares

Author's Avatar
Jun 24, 2009
CEO of Keryx Biopharmaceuticals Inc. (KERX, Financial) Ron Bentsur buys 5,560 shares of KERX on 06/23/2009 at an average price of $0.9 a share.

Keryx Biophamaceutical Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate. Keryx Biopharmaceuticals Inc. has a market cap of $42.4 million; its shares were traded at around $0.885 with and P/S ratio of 33.1.

Recent Trades of Keryx Biopharmaceuticals Inc. by CEO:
  • Buy: CEO Ron Bentsur bought 5,560 shares of KERX stock on 06/23/2009 at the average price of $0.9; the price of the stock has decreased by 1.67% since.

  • Buy: CEO Ron Bentsur bought 80,000 more shares of KERX stock on 05/22/2009 at the average price of $0.37; the price of the stock has increased by 139.19% since.



Recent Trades of Keryx Biopharmaceuticals Inc. by CFO:
  • Buy: CFO James F Iii Oliviero bought 2,750 shares of KERX stock on 06/23/2009 at the average price of $0.9; the price of the stock has decreased by 1.67% since.

  • Buy: CFO James F Iii Oliviero bought 25,000 more shares of KERX stock on 05/22/2009 at the average price of $0.4; the price of the stock has increased by 121.25% since.



Recent Trades of Keryx Biopharmaceuticals Inc. by Directors and Officers:
  • Buy: Director Wyche Jr Fowler bought 20,000 shares of KERX stock on 06/04/2009 at the average price of $1.05; the price of the stock has decreased by 15.71% since.

  • Buy: Director Michael P. Tarnok bought 40,000 shares of KERX stock on 05/26/2009 at the average price of $0.46; the price of the stock has increased by 92.39% since.

  • Buy: Director Jack Kaye bought 35,000 shares of KERX stock on 05/22/2009 at the average price of $0.43; the price of the stock has increased by 105.81% since.